Amoxicillin extended-release - MiddleBrook

Drug Profile

Amoxicillin extended-release - MiddleBrook

Alternative Names: Amoxicillin PULSYS; APC-111; APC-231; Moxatag

Latest Information Update: 09 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Advancis Pharmaceutical
  • Developer MiddleBrook Pharmaceuticals
  • Class Antibacterials; Penicillins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pharyngitis; Tonsillitis

Most Recent Events

  • 02 Oct 2015 Amoxicillin extended release licensed to Vernalis in USA
  • 01 Mar 2014 Pragma Pharmaceuticals acquires amoxicillin extended release from Shionogi
  • 07 Feb 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top